These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 33971856)

  • 21. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
    Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
    Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.
    Nelsen LM; Cockle SM; Gunsoy NB; Jones P; Albers FC; Bradford ES; Mullerova H
    J Asthma; 2020 Sep; 57(9):1006-1016. PubMed ID: 31251094
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis.
    Nachef Z; Krishnan A; Mashtare T; Zhuang T; Mador MJ
    J Asthma; 2018 Jan; 55(1):89-100. PubMed ID: 28459601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
    J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.
    Kim MK; Park HS; Park CS; Min SJ; Albers FC; Yancey SW; Mayer B; Kwon N
    Korean J Intern Med; 2021 Mar; 36(2):362-370. PubMed ID: 32450626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
    Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 38. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.